Parathyroid hormone (PTH) plays a critical role in controlling calcium, phosphate and vitamin D levels in the blood and bones. PTH directly involves the kidneys, bones, muscles, nerves and other organs in maintaining key biological functions. Hypoparathyroidism is a rare condition in which the body fails to produce sufficient amounts of PTH or the PTH produced lacks normal biologic activity.
Over 200,000 people are estimated to be afflicted with hypoparathyroidism worldwide.
Historically, standard treatment for hypoparathyroidism includes calcium supplements, calcitriol or “active vitamin D” analogs and occasionally phosphate binders, the chronic use of which may result in serious side effects and significant costs to patients and healthcare systems.